Chiba University

First Clinical Trial Shows Nicotinamide Riboside Improves Multiple Health Outcomes in Werner Syndrome Patients

- Japanese researchers conducted the world's first rigorous clinical trial of nicotinamide riboside (NR) in Werner syndrome patients, showing significant improvements in cardiovascular health, skin ulcers, and kidney function. - The randomized, double-blind, placebo-controlled crossover trial demonstrated that NR supplementation increased NAD+ blood levels and improved arterial stiffness without serious side effects. - Results suggest NR could address fundamental NAD+ depletion mechanisms in Werner syndrome, offering new hope for patients with this rare premature aging disorder that currently lacks effective treatments. - The study's findings may have broader implications for understanding aging biology and developing interventions for age-related diseases beyond Werner syndrome.